Skip to content
Our 2022 Year in Review is now live.
  • Insights

      Weekly Bulletin

      Your weekly recap of news and analysis from the psychedelic sector.

      Read the Latest

      Research Review

      A monthly review of the most important psychedelics research.

      Review Archive

      News & Interviews

      The latest news from across the psychedelics space.

      Explore Now
  • Data

      Psychedelics Patent Trackers

      We track the latest patents and filings related to psilocybin, MDMA and DMT.

      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents
      Psilocybin Patents
      Psilocybin Patent Filings
      LSD Patents
      MDMA Patents
      DMT Patents

      Psychedelic Legalization & Decriminalization Tracker

      Mapping psychedelic drug policy reform across the United States

      Explore the Tracker
      New: Oregon Local Jurisdiction Tracker

      Psychedelics Drug Development Tracker

      From drug discovery to regulatory approval, we map drug development in psychedelics.

      Explore the Tracker
  • Companies

      Stocks & Companies Directory

      A directory of all the major psychedelics stocks, companies and ETFs.

      Access Directory

      Sector Landscape Map

      Explore the Psychedelic Sector Landscape visually using our new tool.

      Explore Now

      Stock Watchlist

      A one-stop overview of psychedelics stocks financial performance.

      Explore Now
  • Psychedelic Careers
  • Contact
Search
Close
Read more about the article Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

Psilera Confirms PSIL-002, A New DMT Derivative, is Well-Tolerated and Non-Hallucinogenic from In Vivo Behavioral Studies

  • Post published:December 7, 2021
  • Post category:Press Release
Read more about the article Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

Psilera Collaborates with the National Institute on Drug Abuse (NIDA) to Research DMT and New Analogues to Combat Addiction

  • Post published:August 26, 2021
  • Post category:Press Release
Read more about the article Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

Psilera Initiates Landmark Preclinical Studies with New Psychedelic Derivatives aimed at Reducing Alcohol Consumption

  • Post published:August 12, 2021
  • Post category:Press Release
Read more about the article Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

Psilera Raises $2.5 Million with Oversubscribed Series Seed from Leading Institutional Investors to Accelerate Clinical Pipeline Focused on DMT

  • Post published:July 1, 2021
  • Post category:Press Release
Read more about the article Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

Psilera Bioscience Obtains DEA Approval to Conduct Cutting Edge Psychedelics Research

  • Post published:February 25, 2021
  • Post category:Press Release
Read more about the article Jackie von Salm, Co-founder and CSO at Psilera Bioscience

Jackie von Salm, Co-founder and CSO at Psilera Bioscience

  • Post published:December 17, 2020
  • Post category:Interview
Read more about the article Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

Psilera Bioscience Launches State-of-the-Art Computational Research of Psychedelic-Inspired Compound Library

  • Post published:December 16, 2020
  • Post category:Press Release
Read more about the article Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

Psilera Bioscience Announces Award-Winning Executive Team and Flagship Patent Milestone for Future Psychedelic Therapies

  • Post published:July 1, 2020
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Psychedelic Stocks and Companies
  • News & Interviews
  • Psychedelic Sector Jobs
  • Data Bank

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

  • Psychedelic Alpha © 2022, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Join Our Newsletter

Psychedelic sector insights, interviews and analysis delivered to your inbox.

No thanks, continue to site.